Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NN-103
- Development stage
- Preclinical
- Lead developer
- NanoNewron
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NN-103 is a humanized camelid nanobody (single-domain antibody) developed by NanoNewron that targets Transferrin Receptor 1 (TfR1). It serves as a blood-brain barrier (BBB) shuttle platform, marketed under the name NewroBus, designed to facilitate the delivery of therapeutic biologics into the central nervous system. NN-103 utilizes receptor-mediated transcytosis to cross the BBB and is engineered to bind TfR1 without competing with endogenous transferrin or disrupting iron homeostasis. It is currently in preclinical development as a modular platform technology and as a key component of multi-specific therapeutic candidates, such as the TNF-α inhibitor heterotrimer NN-841.
- Other names
- NewroBus
02
Targets
TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on NN-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NN-103.